Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 13, 2007. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 2,150,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,271.16 pence per share.
- Treasury Holdings: 355,462,158 shares (representing 6.27% of total voting rights).
- Shares in Issue: 5,666,734,302 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 2,150,000 shares on August 13, 2007. These shares are held in Treasury. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the repurchase (2,150,000 shares at 1,271.16 pence).
- Confirm the updated total voting rights denominator (5,666,734,302 shares) for disclosure threshold calculations.
- Review the impact of the 6.27% Treasury holding on earnings per share metrics in subsequent reports.
- Check for any remaining authorized share buyback capacity following this transaction.